|
|
|
|
|
10.12.25 - 17:48
|
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ® (GlobeNewswire EN)
|
|
|
Saint-Herblain (France), December 10, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive final antibody persistence and safety data for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children, twelve months after vaccination. Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial results continue to support future Phase 3 development in children, which the Company plans to initiate after gathering additional real-world experience in the adolescent population....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.11.25 - 17:33
|
Valneva to Further Consolidate its Operations in France (GlobeNewswire EN)
|
|
|
Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced a strategic initiative to optimize its organizational footprint in France as part of the Company's ongoing efforts to increase operational effectiveness and position Valneva for long-term success. ...
|
|
|
26.11.25 - 12:48
|
Valneva: Starke Daten zu Hoffnungsträger – Aktie zieht kräftig an (Der Aktionaer)
|
|
|
Positive Studiennews beflügeln zur Wochenmitte die Aktie des Impfstoffherstellers Valneva. Das Unternehmen hat heute neue positive Ergebnisse aus der Phase-2-Studie zum Impfstoffkandidaten VLA15 gegen Lyme-Borreliose gemeldet. Die Daten zeigen sechs Monate nach der dritten Auffrischung eine starke Immunreaktion in allen Altersgruppen und ein weiterhin gutes Sicherheitsprofil....
|
|
|
|
|
|
|
|
|
26.11.25 - 07:03
|
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate (GlobeNewswire EN)
|
|
|
Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15. The results showed strong anamnestic immune response and favorable safety profile six months after a third booster dose (month 48) in all age groups, confirming compatibility with the anticipated benefits of a yearly vaccination prior to each Lyme season. Pfizer and Valneva entered into a collaboration agreement in April 2020 for the development and commercialization of VLA15 by Pfizer....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
